SLN SILENCE THERAPEUTICS PLC revenue, earnings and financials
For the quarter ended June 30, 2026, SILENCE THERAPEUTICS PLC reported revenue of $0 (down 100.0% from a year earlier), net income of −$12.3M and diluted EPS of −$0.09; over the last four quarters revenue was $615K and net income −$60.0M; for the fiscal year ended December 2025 revenue was $559K, down 98.7% on the year before.
SLN annual revenue and earnings
- Fiscal year ended Dec 2025: revenue $559K, gross profit $344K, operating income −$91.1M, net income −$88.6M (margin -15851.5%), EPS −$0.63
- Fiscal year ended Dec 2024: revenue $43.3M, gross profit $31.4M, operating income −$63.3M, net income −$45.3M (margin -104.7%), EPS −$0.33
- Fiscal year ended Dec 2023: revenue $31.6M, gross profit $18.8M, operating income −$64.4M, net income −$54.2M (margin -171.4%), EPS −$0.49
- Fiscal year ended Dec 2022: revenue $21.7M, gross profit $8.19M, operating income −$61.0M, net income −$50.3M (margin -232.4%), EPS −$0.52
SLN quarterly revenue and earnings
- Quarter ended Jun 30, 2026: revenue $0 (down 100.0% year over year), net income −$12.3M, EPS −$0.09
- Quarter ended Mar 31, 2026: revenue $422K (up 197.2% year over year), net income −$15.0M, EPS −$0.11
- Quarter ended Dec 31, 2025 (from the annual report): revenue $34.0K (down 99.9% year over year), net income −$11.8M, EPS −$0.09
- Quarter ended Sep 30, 2025: revenue $159K (down 89.4% year over year), net income −$21.0M, EPS −$0.15
- Quarter ended Jun 30, 2025: revenue $224K (down 70.4% year over year), net income −$27.4M, EPS −$0.19
- Quarter ended Mar 31, 2025: revenue $142K (down 99.1% year over year), net income −$28.5M, EPS −$0.20
- Quarter ended Dec 31, 2024 (from the annual report): revenue $25.3M, net income $12.3M, EPS $0.08
- Quarter ended Sep 30, 2024: revenue $1.50M, net income −$35.5M, EPS −$0.25
- Quarter ended Jun 30, 2024: revenue $756K, net income −$19.8M, EPS −$0.14
- Quarter ended Mar 31, 2024: revenue $15.7M, net income −$2.31M, EPS −$0.02
SLN cash flow, buybacks and dividends
- Fiscal year ended Dec 2025: operating cash flow −$62.3M, share buybacks n/a
- Fiscal year ended Dec 2024: operating cash flow −$67.6M, share buybacks n/a
- Fiscal year ended Dec 2023: operating cash flow −$49.5M, share buybacks n/a
- Fiscal year ended Dec 2022: operating cash flow −$57.0M, share buybacks n/a
SLN balance sheet
- Jun 30, 2026: cash $72.1M, total assets $106M, total liabilities $67.9M, shareholders' equity $38.5M
- Mar 31, 2026: cash $5.66M, total assets $115M, total liabilities $65.7M, shareholders' equity $49.4M
- Dec 31, 2025: cash $11.3M, total assets $131M, total liabilities $69.1M, shareholders' equity $62.3M
- Sep 30, 2025: cash $82.0M, total assets $147M, total liabilities $72.7M, shareholders' equity $74.1M
- Jun 30, 2025: cash $41.7M, total assets $165M, total liabilities $71.1M, shareholders' equity $94.2M
- Mar 31, 2025: cash $64.9M, total assets $185M, total liabilities $72.6M, shareholders' equity $113M
- Dec 31, 2024: cash $121M, total assets $203M, total liabilities $68.6M, shareholders' equity $134M
- Dec 31, 2023: cash $68.8M, total assets $119M, total liabilities $97.5M, shareholders' equity $22.0M
What is SLN's revenue?
SILENCE THERAPEUTICS PLC reported $615K of revenue over its last four quarters, through June 30, 2026.
Is SLN profitable?
No. SILENCE THERAPEUTICS PLC lost $60.0M over the last four quarters.
What is SLN's EPS?
Diluted earnings per share over the last four quarters were −$0.44; −$0.09 in the latest quarter.